Chris Viehbacher to leave GlaxoSmithKline

Share this article:

Chris Viehbacher, GlaxoSmithKline's executive director and president, North American pharmaceuticals, has announced plans to leave the company.

Viehbacher resigned his position on GSK's board on Sept 8, and will leave the company entirely on December 1, 2008, according to a statement. Andrew Witty, currently CEO at GSK, was appointed to that position upon the retirement of CEO Jean-Pierre Garnier last May. Viehbacher had been a contender for the CEO role. 

Witty said of Viehbacher in the statement, “I would like to thank Chris for his significant contribution to GSK, he is one of the most talented and respected executives in this industry and we wish him well in his future endeavors.”

Share this article:
You must be a registered member of MMM to post a comment.

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.